» Articles » PMID: 36364248

Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Nov 11
PMID 36364248
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence has shown that Parkinson's disease (PD) is a systemic disease other than a mere central nervous system (CNS) disorder. One of the most important peripheral symptoms is gastrointestinal dysfunction. The enteric nervous system (ENS) is regarded as an essential gateway to the environment. The discovery of the prion-like behavior of α-synuclein makes it possible for the neurodegenerative process to start in the ENS and spread via the gut-brain axis to the CNS. We first confirmed that synucleinopathies existed in the stomachs of chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/probenecid (MPTP/p)-induced PD mice, as indicated by the significant increase in abnormal aggregated and nitrated α-synuclein in the TH-positive neurons and enteric glial cells (EGCs) of the gastric myenteric plexus. Next, we attempted to clarify the mechanisms in single MPTP-injected mice. The stomach naturally possesses high monoamine oxidase-B (MAO-B) activity and low superoxide dismutase (SOD) activity, making the stomach susceptible to MPTP-induced oxidative stress, as indicated by the significant increase in reactive oxygen species (ROS) in the stomach and elevated 4-hydroxynonenal (4-HNE) in the EGCs after MPTP exposure for 3 h. Additionally, stomach synucleinopathies appear before those of the nigrostriatal system, as determined by Western blotting 12 h after MPTP injection. Notably, nitrated α-synuclein was considerably increased in the EGCs after 3 h and 12 h of MPTP exposure. Taken together, our work demonstrated that the EGCs could be new contributors to synucleinopathies in the stomach. The early-initiated synucleinopathies might further influence neighboring neurons in the myenteric plexus and the CNS. Our results offer a new experimental clue for interpreting the etiology of PD.

Citing Articles

Modulation of Intestinal Inflammation and Protection of Dopaminergic Neurons in Parkinson's Disease Mice through a Probiotic Formulation Targeting NLRP3 Inflammasome.

Zhou L, Wong K, Xie H J Neuroimmune Pharmacol. 2025; 20(1):9.

PMID: 39826038 PMC: 11742874. DOI: 10.1007/s11481-024-10163-5.


Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.


From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson's Disease.

Montalban-Rodriguez A, Abalo R, Lopez-Gomez L Int J Mol Sci. 2024; 25(2).

PMID: 38279293 PMC: 10816228. DOI: 10.3390/ijms25021294.

References
1.
Hayes M . Parkinson's Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807. DOI: 10.1016/j.amjmed.2019.03.001. View

2.
Jackson-Lewis V, Przedborski S . Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007; 2(1):141-51. DOI: 10.1038/nprot.2006.342. View

3.
de Zoete M, Palm N, Zhu S, Flavell R . Inflammasomes. Cold Spring Harb Perspect Biol. 2014; 6(12):a016287. PMC: 4292152. DOI: 10.1101/cshperspect.a016287. View

4.
Kim W, Im M, Park C, Lee C, Choi S, Yoon B . Remodeling of the dendritic structure of the striatal medium spiny neurons accompanies behavioral recovery in a mouse model of Parkinson's disease. Neurosci Lett. 2013; 557 Pt B:95-100. DOI: 10.1016/j.neulet.2013.10.049. View

5.
Liddle R . Parkinson's disease from the gut. Brain Res. 2018; 1693(Pt B):201-206. PMC: 6003841. DOI: 10.1016/j.brainres.2018.01.010. View